{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:23:49Z","timestamp":1759710229174,"version":"build-2065373602"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,6,20]],"date-time":"2020-06-20T00:00:00Z","timestamp":1592611200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Hypotheses"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.mehy.2020.110027","type":"journal-article","created":{"date-parts":[[2020,6,26]],"date-time":"2020-06-26T13:59:02Z","timestamp":1593179942000},"page":"110027","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Why the lower reported prevalence of asthma in patients diagnosed with COVID-19 validates repurposing EDTA solutions to prevent and manage treat COVID-19 disease"],"prefix":"10.1016","volume":"144","author":[{"given":"Daniel P.","family":"Cashman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.mehy.2020.110027_b0005","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/resp.13196","article-title":"MERS, SARS and other coronaviruses as causes of pneumonia","volume":"23","author":"Yin","year":"2018","journal-title":"Respirology"},{"key":"10.1016\/j.mehy.2020.110027_b0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically-proven protease inhibitor","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.mehy.2020.110027_b0015","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3181\/00379727-121-30734","article-title":"A new virus isolated from the human respiratory tract","volume":"121","author":"Hamre","year":"1966","journal-title":"Proc Soc Exp Biol Med"},{"issue":"2","key":"10.1016\/j.mehy.2020.110027_b0020","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1099\/0022-1317-1-2-175","article-title":"The morphology of three previously uncharacterized human respiratory viruses that grow in organ culture","volume":"1","author":"Almeida","year":"1967","journal-title":"J Gen Virol"},{"key":"10.1016\/j.mehy.2020.110027_b0025","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1099\/vir.0.043117-0","article-title":"Differences in neutralizing antigenicity between laboratory and clinical isolates of HCoV-229E isolated in Japan in 2004\u20132008 depend on the S1 region sequence of the spike protein","volume":"93","author":"Shirato","year":"2012","journal-title":"J Gen Virol"},{"key":"10.1016\/j.mehy.2020.110027_b0030","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1128\/JCM.00533-08","article-title":"Human coronavirus NL63 and 229E seroconversion in children","volume":"46","author":"Dijkman","year":"2008","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.mehy.2020.110027_b0035","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/357420a0","article-title":"Human aminopeptidase N is a receptor for human coronavirus 229E","volume":"357","author":"Yeager","year":"1992","journal-title":"Nature"},{"key":"10.1016\/j.mehy.2020.110027_b0040","doi-asserted-by":"crossref","unstructured":"Shirato K, Kanou K, Kawase M, Matsuyama S. Clinical isolates of human coronavirus 229E bypass the endosome for cell entry. J Virol 2017;91:JVI.01387\u201316.","DOI":"10.1128\/JVI.01387-16"},{"key":"10.1016\/j.mehy.2020.110027_b0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.meegid.2020.104212","article-title":"Full-genome evolutionary analysis of the novel corona virus (2019-nCoV) rejects the hypothesis of emergence as a result of a recent recombination event","volume":"79","author":"Paraskevis","year":"2020","journal-title":"Infect Genet Evol"},{"key":"10.1016\/j.mehy.2020.110027_b0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.mehy.2020.110027_b0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.11.032","article-title":"Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein","author":"Walls","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.mehy.2020.110027_b0060","doi-asserted-by":"crossref","unstructured":"Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus. J Virol. 2020;94(7).","DOI":"10.1128\/JVI.00127-20"},{"key":"10.1016\/j.mehy.2020.110027_b0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104742","article-title":"The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade","volume":"176","author":"Coutard","year":"2020","journal-title":"Antiviral Res"},{"issue":"3","key":"10.1016\/j.mehy.2020.110027_b0070","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1006\/geno.1997.4845","article-title":"Cloning of the TMPRSS2 gene, which encodes a novel serine protease with transmembrane, LDLRA, and SRCR domains and maps to 21q22.3","volume":"44","author":"Paoloni-Giacobino","year":"1997","journal-title":"Genomics"},{"key":"10.1016\/j.mehy.2020.110027_b0075","doi-asserted-by":"crossref","unstructured":"Reichhardt MP, Loimaranta V, Lea SM, Johnson S. Structures of SALSA\/DMBT1 SRCR domains reveal the conserved ligand-binding mechanism of the ancient SRCR fold. Life Sci Alliance. 2020;3(4).","DOI":"10.26508\/lsa.201900502"},{"key":"10.1016\/j.mehy.2020.110027_b0080","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1371\/journal.ppat.1004530","article-title":"Rubella virus: first calcium-requiring viral fusion protein","volume":"10","author":"Dub\u00e9","year":"2014","journal-title":"PLoS Pathog"},{"issue":"24","key":"10.1016\/j.mehy.2020.110027_b0085","doi-asserted-by":"crossref","first-page":"3875","DOI":"10.1016\/j.jmb.2017.10.017","article-title":"The SARS-CoV fusion peptide forms an extended bipartite fusion platform that perturbs membrane order in a calcium-dependent manner","volume":"429","author":"Lai","year":"2017","journal-title":"J Mol Biol"},{"issue":"4","key":"10.1016\/j.mehy.2020.110027_b0090","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1080\/17460441.2019.1581171","article-title":"Bavari S Broad-spectrum coronavirus antiviral drug discovery","volume":"14","author":"Totura","year":"2019","journal-title":"Expert Opin Drug Discov"},{"issue":"9","key":"10.1016\/j.mehy.2020.110027_b0095","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0030343","article-title":"SARS: systematic review of treatment effects","volume":"3","author":"Stockman","year":"2006","journal-title":"PLoS Med"},{"issue":"3","key":"10.1016\/j.mehy.2020.110027_b0100","doi-asserted-by":"crossref","DOI":"10.1002\/rmv.1977","article-title":"Clinical outcomes of current medical approaches for Middle East respiratory syndrome: a systematic review and meta-analysis","volume":"28","author":"Morra","year":"2018","journal-title":"Rev Med Virol"},{"issue":"10223","key":"10.1016\/j.mehy.2020.110027_b0105","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0140-6736(20)30317-2","article-title":"Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury","volume":"395","author":"Russell","year":"2020","journal-title":"Lancet"},{"issue":"2 Pt 2","key":"10.1016\/j.mehy.2020.110027_b0110","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1016\/S0091-6749(99)70274-5","article-title":"Bronchoconstrictor additives in bronchodilator solutions","volume":"104","author":"Asmus","year":"1999","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.mehy.2020.110027_b0115","unstructured":"Beasley R, Effect of EDTA on the bronchodilator response to Duovent nebulizer solution. NZ Med J. 1989;102(871):357."},{"issue":"4","key":"10.1016\/j.mehy.2020.110027_b0120","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jcf.2006.03.007","article-title":"Inhalation solutions: which one are allowed to be mixed? Physico-chemical compatibility of drug solutions in nebulizers","volume":"5","author":"Kamin","year":"2006","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.mehy.2020.110027_b0125","unstructured":"see <https:\/\/www.drugs.com\/pro\/metaproterenol.html>."},{"issue":"6581","key":"10.1016\/j.mehy.2020.110027_b0130","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1136\/bmj.294.6581.1197-a","article-title":"S T Holgate Bronchoconstrictor properties of preservatives in ipratropium bromide (Atrovent) nebuliser solution","volume":"294","author":"Beasley","year":"1987","journal-title":"Br Med J (Clin Res Ed)"},{"issue":"6581","key":"10.1016\/j.mehy.2020.110027_b0135","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1136\/bmj.294.6581.1197-a","article-title":"Bronchoconstrictor properties of preservatives in ipratropium bromide (Atrovent) nebulizer solution","volume":"294","author":"Beasley","year":"1987","journal-title":"Br Med J (Clin Res Ed)"},{"issue":"5","key":"10.1016\/j.mehy.2020.110027_b0140","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1152\/jappl.1991.71.5.1848","article-title":"Functional antagonism of airway constriction in the canine lung periphery","volume":"71","author":"Lindeman","year":"1991","journal-title":"J Appl Physiol"},{"issue":"12","key":"10.1016\/j.mehy.2020.110027_b0145","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1001\/jama.2013.2107","article-title":"Effect of disodium EDTA chelation regimen on cardiovascular events in patients with previous myocardial infarction: the TACT randomized trial","volume":"309","author":"Lamas","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.mehy.2020.110027_b0150","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1177\/106002809302701217","article-title":"So much writing, so little science: a review of 37 years of literature on edetate sodium chelation therapy","volume":"27","author":"Grier","year":"1993","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.mehy.2020.110027_b0155","unstructured":"See NIH RFA <https:\/\/grants.nih.gov\/grants\/guide\/rfa-files\/RFA-AT-01-004.html> EDTA CHELATION THERAPY FOR CORONARY ARTERY DISEASE Release Date: April 30 RFA: 2001 National Center for Complementary and Alternative Medicine RFA-AT-01-004."},{"key":"10.1016\/j.mehy.2020.110027_b0160","doi-asserted-by":"crossref","unstructured":"Knudtson ML, Wyse DG, Galbraith PD. et al. Chelation therapyforischemic heart disease: arandomized controlled trial. JAMA. 2002;287(4):481\u20136.","DOI":"10.1001\/jama.287.4.481"},{"key":"10.1016\/j.mehy.2020.110027_b0165","unstructured":"Halpin DMG, Faner R, Sibila O, Badia JR, Agusti A. Do chronic respiratory diseases or their treatment affect the risk of SARS-CoV-2 infection? Lancet Respir Med.2020 Apr 3. pii: S2213-2600(20)30167-3."},{"key":"10.1016\/j.mehy.2020.110027_b0170","doi-asserted-by":"crossref","unstructured":"Bhatraju PK, Ghassemieh BJ, Nichols M, et al, COVID-19incriticallyillpatientsin theseattleregion \u2013 case series N Engl J Med. 2020.","DOI":"10.1056\/NEJMoa2004500"},{"key":"10.1016\/j.mehy.2020.110027_b0175","doi-asserted-by":"crossref","unstructured":"Boratyn GM,Camacho C,Cooper PS,et al. BLAST: amoreefficientreportwithusabilityimprovements. Nucleic Acids Res.2013;41 (Web Server issue):W29-33.","DOI":"10.1093\/nar\/gkt282"},{"issue":"1","key":"10.1016\/j.mehy.2020.110027_b0180","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1080\/22221751.2020.1736644","article-title":"A tug-of war between severe acute respiratory syndrome coronavirus 2 and host antiviral defense: lessons from other pathogenic viruses","volume":"9","author":"Fung","year":"2020","journal-title":"Emerg Microbes Infect"},{"key":"10.1016\/j.mehy.2020.110027_b0185","unstructured":"See PubChem Ethylenediaminetetraacetic acid disodium salt (Compound); <https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Ethylenediaminetetraacetic-acid-disodium-salt#section=Absorption-Distribution-and-Excretion>."},{"key":"10.1016\/j.mehy.2020.110027_b0190","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/978-1-4899-7448-8_10","article-title":"Coronaviruses","volume":"27","author":"Monto","year":"2014","journal-title":"Viral Infect Humans"},{"issue":"2","key":"10.1016\/j.mehy.2020.110027_b0195","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1017\/S0950268800048019","article-title":"The time course of the immune response to experimental coronavirus infection of man","volume":"105","author":"Callow","year":"1990","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.mehy.2020.110027_b0200","unstructured":"U.S. Considering COVID-19 Immunity Cards: What Does ItMean? <https:\/\/heavy.com\/news\/2020\/04\/coronavirus-immunity-cards\/>."},{"issue":"Suppl 2","key":"10.1016\/j.mehy.2020.110027_b0205","first-page":"95","article-title":"Final report on the safety assessment of EDTA, calcium disodium EDTA, diammonium EDTA, dipotassium EDTA, disodium EDTA, TEA-EDTA, tetrasodium EDTA, tripotassium EDTA, trisodium EDTA, HEDTA, and trisodium HEDTA","volume":"21","author":"Lanigan","year":"2002","journal-title":"Int J Toxicol"}],"container-title":["Medical Hypotheses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987720312007?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987720312007?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T19:28:35Z","timestamp":1759692515000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306987720312007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":41,"alternative-id":["S0306987720312007"],"URL":"https:\/\/doi.org\/10.1016\/j.mehy.2020.110027","relation":{},"ISSN":["0306-9877"],"issn-type":[{"type":"print","value":"0306-9877"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Why the lower reported prevalence of asthma in patients diagnosed with COVID-19 validates repurposing EDTA solutions to prevent and manage treat COVID-19 disease","name":"articletitle","label":"Article Title"},{"value":"Medical Hypotheses","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mehy.2020.110027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"110027"}}